Antibody Screening - Unravelling the full potential of entire immune repertoires (millions of B cells) VERAXA´s unique platform can combine the assessment of antibody binding with its functional capabilities in 1 single screening step, using a proprietary droplet-based microfluidic screening workstation ADC Technology - Functionalizing UAA-antibodies with click chemistry VERAXA‘s superior antibody labeling technologies allow conjugation of any given antibody at almost every position, to compete with the most prominent challenges in antibody-drug conjugate (ADC) and radioimmunoconjugates (RIC) drug development.